ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET
ANI Pharmaceuticals (Nasdaq: ANIP) will release its third quarter 2025 financial results on Friday, November 7, 2025 prior to market open.
A conference call with Nikhil Lalwani (CEO), Stephen P. Carey (CFO) and Chris Mutz (Head of Rare Disease) will be held on November 7, 2025 at 8:30 a.m. ET. Investors can join by dialing the U.S. toll-free number 800-267-6316 using conference ID 5120265 or via live webcast at www.anipharmaceuticals.com under the Investors section.
A replay will be available about two hours after the call and remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265.
ANI Pharmaceuticals (Nasdaq: ANIP) annuncerà i suoi risultati finanziari del terzo trimestre 2025 venerdì 7 novembre 2025 prima dell'apertura del mercato.
Una telefonata conferenza con Nikhil Lalwani (CEO), Stephen P. Carey (CFO) e Chris Mutz (Head of Rare Disease) si terrà il 7 novembre 2025 alle 8:30 ora ET. Gli investitori possono partecipare chiamando il numero verde statunitense 800-267-6316 utilizzando l'ID di conferenza 5120265 o tramite webcast in diretta su www.anipharmaceuticals.com nella sezione Investitori.
Una replica sarà disponibile circa due ore dopo la chiamata e resterà accessibile per due settimane chiamando 800-839-2391 e inserendo il codice di accesso 5120265.
ANI Pharmaceuticals (Nasdaq: ANIP) publicará sus resultados financieros del tercer trimestre de 2025 el viernes 7 de noviembre de 2025 antes de la apertura del mercado.
Una conferencia telefónica con Nikhil Lalwani (CEO), Stephen P. Carey (CFO) y Chris Mutz (Head of Rare Disease) se llevará a cabo el 7 de noviembre de 2025 a las 8:30 a.m. ET. Los inversionistas pueden unirse marcando el número gratuito de EE. UU. 800-267-6316 usando la ID de conferencia 5120265 o a través del webcast en vivo en www.anipharmaceuticals.com en la sección de Inversionistas.
Habrá una repetición disponible aproximadamente dos horas después de la llamada y estará accesible durante dos semanas llamando al 800-839-2391 e ingresando el código de acceso 5120265.
ANI Pharmaceuticals (나스닥: ANIP)는 2025년 3분기 재무 실적을 2025년 11월 7일 금요일 시장 개장 전에 발표합니다.
CEO인 Nikhil Lalwani, CFO인 Stephen P. Carey, Rare Disease 책임자 Chris Mutz 와의 컨퍼런스 콜은 2025년 11월 7일 오전 8:30 ET에 개최됩니다. 투자자는 미국 내 무료 전화번호 800-267-6316으로 컨퍼런스 ID 5120265를 사용하거나 www.anipharmaceuticals.com의 투자자(Investors) 섹션에서 생중계에 접속하여 참여할 수 있습니다.
대체 방송은 콜 종료 약 2시간 후에 이용 가능하며 2주간 계속해서 800-839-2391로 전화하고 접속 코드 5120265를 입력하여 이용할 수 있습니다.
ANI Pharmaceuticals (Nasdaq: ANIP) publiera ses résultats financiers du troisième trimestre 2025 le vendredi 7 novembre 2025 avant l'ouverture du marché.
Une conférence téléphonique avec Nikhil Lalwani (CEO), Stephen P. Carey (CFO) et Chris Mutz (Head of Rare Disease) aura lieu le 7 novembre 2025 à 8h30 ET. Les investisseurs peuvent rejoindre en composant le numéro sans frais des États-Unis 800-267-6316 en utilisant l'identifiant de conférence 5120265 ou via le webcast en direct sur www.anipharmaceuticals.com dans la section Investisseurs.
Une rediffusion sera disponible environ deux heures après l'appel et restera accessible pendant deux semaines en composant le 800-839-2391 et en saisissant le code d'accès 5120265.
ANI Pharmaceuticals (Nasdaq: ANIP) wird seine Ergebnisse für das dritte Quartal 2025 am Freitag, 7. November 2025 vor Handelsbeginn veröffentlichen.
Eine Telefonkonferenz mit Nikhil Lalwani (CEO), Stephen P. Carey (CFO) und Chris Mutz (Head of Rare Disease) findet am 7. November 2025 um 8:30 Uhr ET statt. Investoren können teilnehmen, indem sie die gebührenfreie US-Telefonnummer 800-267-6316 wählen und die Konferenz-ID 5120265 eingeben oder über den Live-Webcast unter www.anipharmaceuticals.com im Bereich Investors.
Eine Wiederholung ist etwa zwei Stunden nach dem Anruf verfügbar und rund zwei Wochen lang erreichbar, indem man 800-839-2391 wählt und den Zugangscode 5120265 eingibt.
ANI Pharmaceuticals (بورصة ناسداك: ANIP) ستصدر نتائجها المالية للربع الثالث من عام 2025 في يوم الجمعة 7 نوفمبر 2025 قبل افتتاح السوق.
سيعقد اتصال هاتفي مع نيخيل لالواني (المدير التنفيذي), ستيفن كيري (المدير المالي) وكريس موتز (رئيس قسم الأمراض النادرة) في 7 نوفمبر 2025 الساعة 8:30 صباحاً بتوقيت شرق الولايات المتحدة. يمكن للمستثمرين الانضمام بالاتصال بالرقم المجاني الأميركي 800-267-6316 باستخدام معرف المؤتمر 5120265 أو عبر البث المباشر على الويب في www.anipharmaceuticals.com ضمن قسم المستثمرين.
سيكون هناك إعادة بث متاحة بعد حوالي ساعتين من الاتصال وستبقى متاحة لمدة أسبوعين عبر الاتصال بـ 800-839-2391 وإدخال رمز الدخول 5120265.
ANI Pharmaceuticals（纳斯达克股票代码：ANIP） 将在市场开盘前公布其 2025 年第三季度 财务业绩，时间为 2025 年 11 月 7 日星期五。
与 Nikhil Lalwani（CEO）、Stephen P. Carey（CFO）和 Chris Mutz（Rare Disease 部门负责人）进行的电话会议将于 2025 年 11 月 7 日 8:30 a.m. 东部时间 举行。投资者可拨打美国免费电话 800-267-6316，使用会议ID 5120265 参与，或通过位于 www.anipharmaceuticals.com 投资者栏目中的直播网络收听。
通话约两小时后将提供回放，回放可通过拨打 800-839-2391，输入访问码 5120265 在两周内访问。
- None.
- None.
PRINCETON, N.J., Oct. 24, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that the Company will release its third quarter 2025 financial results on Friday, November 7, 2025, prior to the market open.
Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a conference call to discuss the results as follows:
| Date | Friday, November 7, 2025 |
| Time | 8:30 a.m. ET |
| Toll free (U.S.) | 800-267-6316 |
| Conference ID | 5120265 |
| Webcast (live and replay) | www.anipharmaceuticals.com, under the “Investors” section |
A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-839-2391 and entering access code 5120265.
About ANI
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Brands business. For more information, visit www.anipharmaceuticals.com.
Investor Relations:
Courtney Mogerley, Argot Partners
T: 646-368-8014
E: ani@argotpartners.com
FAQ
When will ANI Pharmaceuticals (ANIP) release Q3 2025 financial results?
What time is the ANI Pharmaceuticals (ANIP) earnings call on November 7, 2025?
How can I join the ANIP Q3 2025 conference call by phone?
Where can investors watch the ANIP live webcast and replay for Q3 2025?
When and how long will the ANIP earnings call replay be available?
Who will host ANI Pharmaceuticals' Q3 2025 earnings call?
